secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069155
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta Q2 net loss narrows to $22.6M; RSV study enrollment target met
---------------------------------------------------------------------

- Revenue $14.9M, down 13% YoY from $17.1M; net loss $22.6M ($1.06 loss per share) vs $31.2M ($1.47) in prior year.
- Cash and marketables $193.4M at March 31; plus $33.8M tax refund in April; expects runway into fiscal 2028.
- Phase 2 RSVHR study of zelicapavir met enrollment target of 180 high-risk adults; topline data expected late Q3 2025.
- STAT6 program: plan to select development candidate in 2H 2025; KIT inhibitor EPS-1421 IND-enabling studies ongoing.
- Filed opening brief in patent infringement appeal against Pfizer over Paxlovid; original case filed June 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017025069155/0000950170-25-069155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017025069155/enta-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer